Immutep (ASX: IMM) — Company Overview, News & Financial Data
Immutep develops LAG-3 targeted immunotherapies for cancer and autoimmune diseases with clinical-stage product candidates.
Immutep
Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company specializes in Lymphocyte Activation Gene-3 therapeutics, leveraging its understanding of immune cell regulation to create targeted biologic candidates. Its pipeline includes soluble LAG-3 proteins designed to activate antigen-presenting cells and enhance T cell responses against solid tumors, including non-small cell lung cancer, head and neck carcinoma, and breast cancer. The company also develops agonist antibodies to selectively suppress autoreactive T cells in autoimmune conditions, while maintaining strategic out-licensing partnerships with global pharmaceutical companies for clinical-stage antagonist antibody assets.
Snapshot
Operations
Products and/or services of Immutep
- Soluble LAG-3 Fusion Protein for Lung Cancer: This lead clinical asset targets antigen-presenting cells to activate innate and adaptive immunity, serving as a late-stage oncology candidate evaluated in global Phase 3 clinical trials alongside anti-PD-1 immunotherapy.
- Soluble LAG-3 Fusion Protein for Head and Neck Cancer: This clinical program evaluates a soluble recombinant fusion protein administered alongside immune checkpoint blockers in late-stage clinical trials to treat patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma.
- Soluble LAG-3 Fusion Protein for Breast and Solid Tumors: This therapeutic program investigates dose escalation and combination treatments with chemotherapy and targeted agents across clinical trials targeting metastatic breast cancer, soft tissue sarcoma, and multiple solid tumor indications.
- Selective Agonist LAG-3 Antibody for Autoimmune Diseases: This proprietary monoclonal antibody selectively targets and suppresses autoreactive T cells in early clinical development, aiming to control tissue inflammation and treat underlying autoimmune conditions without inducing general immunosuppression.
- Out-Licensed Antagonist LAG-3 Oncology Antibodies: This biopharmaceutical licensing segment partners antagonist monoclonal antibody intellectual property with global pharmaceutical corporations, earning milestone payments and royalties as partners advance combination immunotherapies through clinical evaluation.
- Out-Licensed Autoimmune LAG-3 Programs: This corporate partnership activity licenses targeted lymphocyte-modulating antibody candidates to international pharmaceutical partners, advancing specialized therapeutic assets through clinical trials targeting inflammatory and autoimmune diseases worldwide.
Immutep executive team
- Mr. Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director
- Ms. Deanne Miller LLBCOO, General Counsel & Joint Company Secretary
- Dr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Executive Director
- Mr. Christian Mueller BBA, MSc.Chief Development Officer
- Dr. Stephan Winckels M.D., Ph.D.Chief Medical Officer
- Ms. Indira NaiduJoint Company Secretary